BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)

Reuters

18 Mar

BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)

March 17 (Reuters) - Nanobiotix SA NANOB.PA:

NANOBIOTIX STRENGTHENS FINANCIAL POSITION THROUGH AMENDMENT OF GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) AND EXTENDS CASH VISIBILITY TO MID-2026
NANOBIOTIX SA - AMENDS LICENSING AGREEMENT WITH JOHNSON & JOHNSON
NANOBIOTIX SA - JOHNSON & JOHNSON TO COVER MOST COSTS FOR NANORAY-312 TRIAL
NANOBIOTIX SA - DEAL VALUE ADJUSTED FROM $2.7B TO $2.6B
NANOBIOTIX SA - REVISIONS TO FUTURE MILESTONE PAYMENTS TOTAL $105M
NANOBIOTIX SA - POTENTIAL ADDITIONAL MILESTONES OF $650M FOR FIVE NEW INDICATIONS
NANOBIOTIX SA: AMENDED AGREEMENT ENABLED NANOBIOTIX TO STRENGTHEN FINANCIAL POSITION, EXTENDING CASH VISIBILITY TO MID-2026

Source text: ID:nGNX4N88Cp

Further company coverage: NANOB.PA

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520668911"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520668911\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2520668911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-18 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520668911","market":"nz","top_or_hot":-1,"title":"BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)</title></head><body><p><span>March 17 (Reuters)</span><span> - </span>Nanobiotix SA <span>NANOB.PA</span>:</p><ul><li><p>NANOBIOTIX STRENGTHENS FINANCIAL POSITION THROUGH AMENDMENT OF GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) AND EXTENDS CASH VISIBILITY TO MID-2026</p></li><li><p>NANOBIOTIX SA - AMENDS LICENSING AGREEMENT WITH JOHNSON &amp; JOHNSON</p></li><li><p>NANOBIOTIX SA - JOHNSON &amp; JOHNSON TO COVER MOST COSTS FOR NANORAY-312 TRIAL</p></li><li><p>NANOBIOTIX SA - DEAL VALUE ADJUSTED FROM $2.7B TO $2.6B</p></li><li><p>NANOBIOTIX SA - REVISIONS TO <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> MILESTONE PAYMENTS TOTAL $105M</p></li><li><p>NANOBIOTIX SA - POTENTIAL ADDITIONAL MILESTONES OF $650M FOR FIVE NEW INDICATIONS</p></li><li><p>NANOBIOTIX SA: AMENDED AGREEMENT ENABLED NANOBIOTIX TO STRENGTHEN FINANCIAL POSITION, EXTENDING CASH VISIBILITY TO MID-2026</p></li></ul><p>Source text: <span>ID:nGNX4N88Cp</span></p><p>Further company coverage: <span>NANOB.PA</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-18 05:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)</title></head><body><p><span>March 17 (Reuters)</span><span> - </span>Nanobiotix SA <span>NANOB.PA</span>:</p><ul><li><p>NANOBIOTIX STRENGTHENS FINANCIAL POSITION THROUGH AMENDMENT OF GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) AND EXTENDS CASH VISIBILITY TO MID-2026</p></li><li><p>NANOBIOTIX SA - AMENDS LICENSING AGREEMENT WITH JOHNSON &amp; JOHNSON</p></li><li><p>NANOBIOTIX SA - JOHNSON &amp; JOHNSON TO COVER MOST COSTS FOR NANORAY-312 TRIAL</p></li><li><p>NANOBIOTIX SA - DEAL VALUE ADJUSTED FROM $2.7B TO $2.6B</p></li><li><p>NANOBIOTIX SA - REVISIONS TO <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> MILESTONE PAYMENTS TOTAL $105M</p></li><li><p>NANOBIOTIX SA - POTENTIAL ADDITIONAL MILESTONES OF $650M FOR FIVE NEW INDICATIONS</p></li><li><p>NANOBIOTIX SA: AMENDED AGREEMENT ENABLED NANOBIOTIX TO STRENGTHEN FINANCIAL POSITION, EXTENDING CASH VISIBILITY TO MID-2026</p></li></ul><p>Source text: <span>ID:nGNX4N88Cp</span></p><p>Further company coverage: <span>NANOB.PA</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUA60NZWD:1","article_id":"2520668911","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520668911","pubTimestamp":1742246249,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)March 17 (Reuters) - Nanobiotix SA NANOB.PA:NANOBIOTIX STRENGTHENS FINANCIAL POSITION THROUGH AMENDMENT OF GLOBAL LICENSING AGRE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Nanobiotix修改JNJ-1900(NBTXR3)的全球许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"BRIEF-Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)March 17 (Reuters) - Nanobiotix SA NANOB.PA:NANOBIOTIX STRENGTHENS FINANCIAL POSITION THROUGH AMENDMENT OF GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) AND EXTENDS CASH VISIBILITY TO MID-2026NANOBIOTIX SA - AMENDS LICENSING AGREEMENT WITH JOHNSON & JOHNSONNANOBIOTIX SA - JOHNSON & JOHNSON TO COVER MOST COSTS FOR NANORAY-312 TRIALNANOBIOTIX SA - DEAL VALUE ADJUSTED FROM $2.7B TO $2.6BNANOBIOTIX SA - REVISIONS TO FUTURE MILESTONE PAYMENTS TOTAL $105MNANOBIOTIX SA - POTENTIAL ADDITIONAL MILESTONES OF $650M FOR FIVE NEW INDICATIONSNANOBIOTIX SA: AMENDED AGREEMENT ENABLED NANOBIOTIX TO STRENGTHEN FINANCIAL POSITION, EXTENDING CASH VISIBILITY TO MID-2026Source text: ID:nGNX4N88CpFurther company coverage: NANOB.PA ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}